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The late effects and quality of life (QoL) in childhood acute leukemia survivors were compared between
hematopoietic stem cell transplantation (HSCT) recipients and patients who underwent conventional
therapy. The study included 943 patients, 256 of whom underwent HSCT (27.1%). Medical visits were con-
ducted to detect the occurrence of physical late effects. Based on patient age, different questionnaires were
used to assess QoL. To evaluate the association between HSCT and each type of late effect or QoL dimension,
the appropriate multivariate regressions were performed. QoL mean scores were compared with those ob-
tained for age- and sex-matched French control subjects. Of all the survivors, 674 (71.5%) had at least 1 late
effect, with the risk being 5.0 CI95 (3.0-8.6) times higher for transplantation survivors. For child survivors,
scoring of QoL showed no signiﬁcant differences between the treatment groups. The adult HSCT survivors
reported lower physical dimension QoL scores than chemotherapy survivors. Compared with French norms,
the survivor group reported a signiﬁcantly lower mental composite score; however, the physical composite
score showed no signiﬁcant difference. Thus, transplanted survivors have a high risk of developing late
effects, resulting in a decreased physical well-being in adulthood. However, long after treatment completion,
childhood leukemia survivors report that effects on psychological well-being are more important than they
are in physical QoL dimensions.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION initiated in 2003 with the aim of studying the long-term
Regular advances in cancer treatment have dramatically
changed the prognosis of children with acute leukemia.
Survival rates have increased in the past few decades [1,2],
beneﬁtingmore than85%of childrenwith acute lymphoblastic
leukemia (ALL) and more than 65% of children with acute
myelogenous leukemia (AML) [2]. These substantial improve-
mentshave raised concerns about thedifﬁculties survivors and
their families face, including the late physical effects, problems
with social integration, and decreased quality of life (QoL).
Hematopoietic stem cell transplantation (HSCT) remains
a high-risk treatment for childhood leukemia patients with
potential severe adverse effects [3-6]. Currently, a substantial
proportion of survivors have undergone HSCT, and most
children experience at least 1 late-onset physical effect [7].
Both physical and psychological effects have long-term
consequences for children and their families, leading to an
interest in assessing QoL as well as clinical follow-up for
surviving children [8,9].
In France, the LEA cohort (Leucémie de l’Enfant et
de l’Adolescent [childhood and adolescent leukemia]) wasdgments on page 1071.
quests: Julie Berbis, MD, Laboratoire de
e de Marseille 27, Bd Jean Moulin, 13385
-hm.fr (J. Berbis).
2013 American Society for Blood and Marrow
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January 1980. Initial results, on a relatively small sample,
have found that in spite of a higher risk of physical sequelae
after HSCT than after conventional therapy, very few clini-
cally signiﬁcant differences in QoL were detectable [10].
Otherwise, few studies that have explored the impact of
HSCT are currently available [11-14].
Using the 5-year data collected from the described cohort,
the aim of this study was to produce an update of the ﬁrst
results published on the French LEA cohort [10], comparing
HSCT with conventional treatment on late effects and QoL
among childhood leukemia survivors.METHODS
Subjects
The LEA cohort is a multicenter historical and prospective cohort of
prevalent cases (diagnosed between the January 1, 1980 and the participa-
tion start date of the center) and incident cases (diagnosed after the
participation start date of the center). From 2004 to 2009, the LEA program
consisted of an exhaustive recruitment in 5 French pediatric cancer centers
(Marseilles, Nancy, Nice, Clermont-Ferrand, and Grenoble).
The following four inclusion criteria were used: (1) diagnosis of de novo
AML or de novo ALL since January 1980, not excluding secondary leukemias;
(2) younger than age 18 years at the time of the diagnosis; (3) complete
remission 24 months after the diagnosis for AML patients and ALL patients
grafted in ﬁrst complete remission, or complete remission at 48 months
after the diagnosis for ALL patients not grafted in ﬁrst complete remission;
and (4) agreement to to participate in the study, with parents or legalTransplantation.
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18 years.
This study was approved by a review board (CNIL). All patients included
during 2004 to 2009 were analyzed in the present study.
Evaluation of Medical Health Status
Clinical data relating to acute leukemiawere obtained by reviewing each
medical record. The four types of data reported were as follows: (1) subtype
of leukemia, (2) age at time of diagnosis, (3) disease evolution and relapse
occurrence, and (4) detailed history of treatments received, with special
emphasis on chemotherapy drugs, use of radiotherapy, and HSCT. Medical
visits were conducted to detect the occurrence of late effects based on
clinical examinations and adequate laboratory exams.
Patient height, weight, and body mass index were measured at the time
of diagnosis and on evaluation; values were compared with normality and
converted to standard deviation scores (SDs) using tables of normal values
for the French population [15,16]. The cumulative change in SDs was
calculated as the SDs at the time of the evaluation visit minus the SDs at
diagnosis. The overweight variable was deﬁned as a body mass index of 25
or more for adults (minor if 25.0-29.9 and major if 30 or more) and by
a cumulative SD change of þ1 or more for children under 18 (minor for
a value between 1.0 and 1.9 and major for a value equal to or higher than 2).
Height growth failure was deﬁned using a cumulative SD change equal to or
lower than 1 (minor for a value between1.0 and1.9 and major for a value
equal to or lower than 2).
A growth hormone deﬁciency was diagnosed using the measurement of
growth hormone and insulin-like growth factor 1 after a minimum of 2
stimulation tests. Children were considered not assessable for gonadal
function if they were younger than age 15 years and had never had
menarche (girls) or did not exhibit any pubertal signs (boys). A gonadal side
effect was deﬁned by a hypergonadotropic hypogonadism or by the occur-
rence of precocious puberty. Hypothyroidism was deﬁned as a nontransient
elevation of thyroid-stimulating hormone.
A cardiac side effect was deﬁned as an abnormal decrease in the echo-
cardiographic shortening fraction or the requirement of a speciﬁc treatment.
An ophthalmological evaluation for detecting cataracts was performed. Iron
overload was deﬁned as a serum ferritin dosage 350 ng/mL in the absence
of concomitant abnormal erythrocyte sedimentation rate.
From 2007 to 2009, the assessment of metabolic syndrome was
systematically proposed to all adults with a new LEA health status evalua-
tion. Metabolic syndromewas deﬁned according to the National Cholesterol
Evaluation Program Adult Treatment Panel III, revised in 2005 [17]. During
the same 2007-2008 period, femoral neck and lumbar bone mineral density
was measured using dual-energy x-ray absorptiometry for all adults. A
deﬁcit was deﬁned as a Z (SD) score nomore than2 in at least 1 of the 2 sites
examined. For the “second tumor” item, all second malignancies (including
basal cell carcinoma) and meningioma were taken into consideration.
A viral side effect was deﬁned if positive for hepatitis B surface antigen,
HIV, or hepatitis C virus with a detectable viral load. Other late effects re-
ported were osteonecrosis, diabetes, severe neurological dysfunctions, and
alopecia.
Evaluation of the Quality of Life
TheQoLof adult patientswas assessed using the SF-36 questionnaire [18],
a reliable instrument in assessing self-perceived health status in adult survi-
vors of childhood cancer [19]. The SF-36 is composed of 36 items describing 8
dimensions: physical functioning, social functioning, role limitations due to
physical health problems, role limitations due to emotional problems, general
mental health, vitality, bodily pain, and general health perceptions (Table S1).
Additionally, 2 summary composite scores are generated, namely the physical
composite score and the mental composite score.
The QoL of children and adolescents 8 to 17 years of age was reported by
their parents using the VSP-A questionnaire (Vécu et Santé Perçue de
l’Adolescent et de l’enfant) [20-22]. The 37-item parent version (VSP-Ap),
designed to be answered by parents of children or by adolescents of all ages,
was used. The questionnaire responses described 9 dimensions and
a summary score: psychological well-being, body image, vitality, physical
well-being, leisure activities, relationships with friends, relationships with
parents, relationships with teachers, and school work; it also described 1
complementary dimension, relationships with medical staff (Table S1).
For both the SF-36 and the VSP-Ap, all scores range between 0 and 100,
with higher scores indicating better QoL. The French general population
reference values for both adults [23] and children and adolescents age 8 to 17
years [20] are available for gender- and age-matched comparison purposes.
Statistical Methods
Binary variables were summarized using counts and percentages and
continuous variables with means and SDs. To assess the representativenessof our sample, demographic and clinical variables between the respondent
and nonrespondent groups were compared using chi-square tests (for
percentages) and Student t-tests (for means).
To determine the link between the occurrence for each explored
sequelae and treatment type, HSCT or chemotherapy, adjusted logistic
regression models were performed. The following covariates were included
in themodels: gender, type of leukemia, relapse (yes or no), age at diagnosis,
follow-up duration (between diagnosis and evaluation), central nervous
system irradiation (yes or no), and decade of the start of treatment. Adjusted
odds ratios and risk of having 1 type of late effect (including 95% conﬁdence
intervals) were estimated.
Similarly, adjusted multiple linear regression models were constructed
to explore the link between the patient’s long-term QoL scores and treat-
ment type with the same covariates. Each model is presented with its
standardized b coefﬁcient, measuring the strength of the effect of trans-
plantation on the QoL dimension’s score. The goodness of ﬁt of the models
was measured using adjusted R-squared values. We divided the HSCT group
into 2 subgroups with or without posttransplantation chronic graft-versus-
host disease (cGVHD) and compared health status and QoL of each of them
with the conventional chemotherapy group.
To help interpret the clinical signiﬁcance of differences in the QoL
dimension mean scores, effect sizes were calculated by dividing the differ-
ence between the mean score of the HSCT group and the mean score of the
chemotherapy group by the SD of the chemotherapy group. We considered
an effect size of .2 to .49 as “small,” .5 to .79 as “medium,” and .8 or higher as
“large” [24].
The SF-36 or VSP-Ap mean scores reported by patients were compared
with those obtained for age- and sex-matched French control subjects, using
paired Student t-tests. All tests were 2-sided. Statistical analyses were per-
formed using PASW Statistics software version 17.0.2. (IBM SPSS Inc.,
Chicago, IL).
RESULTS
Study Cohort
Among the 1115 childhood leukemia survivors fulﬁlling
the inclusion criteria in the 5 participant centers, 943
patients agreed to participate in the study (response rate,
84.6%). The respondent group and the nonrespondent group
did not differ signiﬁcantly with respect to the descriptive
variables collected in the medical records (gender, type of
leukemia, age at diagnosis, history of relapse, and treatment
by transplantation or not).
All 943 patients were evaluated during a medical exam-
ination where the current health status and late effects were
documented. The QoL questionnaires were obtained for 761
subjects (80.7%), completed by adults or the survivors’
parents based on survivor age. No signiﬁcant differences
were found between the QoL respondents and nonrespon-
dents for the main sociodemographic and clinical variables.
Patient characteristics are summarized in Table 1. Survi-
vors of the HSCT and chemotherapy groups were not
signiﬁcantly different in follow-up duration from diagnosis
to evaluation, with an average of 11.9  6.4 years. The 256
patients in the HSCT group were signiﬁcantly older by an
average of 1 year at diagnosis and an average of 2 years at the
time of evaluation. The chemotherapy group had a signiﬁ-
cantly lower percentage of males, patients with AML, and
patients with a history of relapse.
Late Effects
Of the survivors, 674 (71.5%) were found to have at least 1
late effect (Table 2). Among the HSCT survivors, 231 (90.2%)
had a late effect, with an average of 3.3  1.8 adverse effects,
whereas in the chemotherapy group, 443 survivors (64.5%)
had a late effect, with an average of 1.6  .8 adverse effects
(P < .001).
After the adjustment, the risk of late effects for the
transplanted group was higher than for the chemotherapy
group. This increased risk was signiﬁcant for each late effect,
with the exception of overweight, bone mineral deﬁciencies,
Table 1
Patient Characteristics
All Patients
(N ¼ 943)
Chemotherapy Group
(N ¼ 687)
HSCT Group
(N ¼ 256)
P
Gender .003*
Female 423 (44.9) 329 (47.9) 94 (36.7)
Male 520 (55.1) 358 (52.1) 162 (63.3)
Leukemia subtype <.001*
ALL 807 (85.6) 630 (91.7) 177 (69.1)
AML 136 (14.4) 57 (8.3) 79 (30.9)
Decade of the start of treatment .027*
1980-1989 192 (20.4) 129 (18.8) 63 (24.6)
1990-1999 417 (44.2) 299 (43.5) 118 (46.1)
2000-2009 334 (35.4) 259 (37.7) 75 (29.3)
Age at diagnosis, yr (mean  SD) 6.4  4.2 6.1  4.0 7.1  4.7 .004*
History of relapse 152 (16.1) 26 (3.8) 126 (49.2) <.001*
Age at evaluation, yr (mean  SD) 18.3  7.1 17.8  7.0 19.6  7.1 <.001*
<8 55 (5.8) 43 (6.3) 12 (4.7)
8-10 102 (10.8) 91 (13.2) 11 (4.3)
11-17 294 (31.2) 211 (30.7) 83 (32.4)
>18 492 (52.2) 342 (49.8) 150 (58.6)
Follow-up duration from diagnosis to evaluation, yr (mean  SD) 11.9  6.4 11.7  6.4 12.5  6.4 .065
CNS irradiation 121 (17.6) 27 (10.5)
Testicular irradiation 10 11
Total body irradiation - 186 (72.7)
Testicular radiation boost - 24
Children who received more than 1HSCT - 14 (5.5)
Hematological status at the time of the ﬁrst transplantation
CR1 - 137 (53.5)
CR2 - 110 (43.0)
More advanced - 9 (.4)
Allogeneic transplantation - 191 (74.6)
Acute GVHD - 112
Chronic GVHD - 51
including chronic GVHD after prior acute GVHD - 39
CNS indicates central nervous system; CR, complete remission.
Values are n (%) unless otherwise noted.
* Signiﬁcant at P < .05.
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viral transmission, in which the differences were not signif-
icant. Among the HSCT survivors, the risk of late effect was
particularly increased for gonadal dysfunction, diabetes,
cataracts, and hypothyroidism, with odds ratios ranging from
24.4 to 29.8 (Table 2).Quality of Life
Parents’ point of view
Regarding patient QoL, parent-reported scoring showed
no signiﬁcant differences between the treatment groups,
except for relationships with teachers and relationships with
medical staff, with a better perception signiﬁcantly associ-
ated with having undergone transplantation. The calculated
effect sizes were less than .2, with the exception of body
image, although this effect was not signiﬁcant (Table 3).
Parents of childhood leukemia survivors reported a signif-
icantly higher perception of their child’s QoL than parents of
the control population, except for psychological well-being,
physical well-being, and relationships with friends. Con-
versely, the survivors’ group reported a signiﬁcantly lower
body image mean score (Figure 1).
Adults
Overall, the HSCT survivors reported lower QoL scores
than the chemotherapy group survivors, and the ﬁndings
were statistically signiﬁcant for physical functioning, bodily
pain, and general health perceptions domains as well as the
physical composite scorewith effect sizes ranging from .31 to
.48 (Table 4). Compared with French population norms,survivors scored signiﬁcantly lower for all domains of QoL
except for general mental health, vitality, bodily pain, and the
physical composite score (Figure 2).DISCUSSION
More than 70% of the survivors and 90.2% of the trans-
plantation survivors in this study developed at least 1 adverse
effect. These ﬁndings are consistent with previous results.
The Childhood Cancer Survivor Study (CCSS) found that 62.3%
of adult survivors of pediatric cancer [25] had a long-term
adverse effect, and Haddy et al. [26] reported sequelae for
74.1% of survivors after treatment for childhood acute
leukemia. Ishida et al. [27] reported 78.0% of adults trans-
planted during childhood reported at least 1 late adverse
effect, whereas Bresters et al. [28] found sequelae for 93.2% of
children and adolescents after HSCT.
Our study reports a substantial effect of HSCT on the
occurrence of late effects, as reported in our previous study,
albeit with a lower level of accuracy [10]. Survivors who
underwent HSCT reported a 5 times greater risk of having at
least 1 adverse effect. Most late effects explored in this study
appeared to be signiﬁcantly more frequent among trans-
plantation patients. In the literature, studies that compared
long-term consequences of HSCT and chemotherapy in child-
hood leukemia are quite rare. Using a relatively small sample,
Leahey et al. [29] reported a signiﬁcant difference for estrogen
supplementation in patients undergoing bone marrow trans-
plantation versus those undergoing chemotherapy. Other
authors [27,30] reported lower adjusted odds ratios than those
in our study in less-homogeneous populations of patients
Table 2
Multivariate Logistic Regression Analyses for the Risk of Having One Type of Late Event
Type of Late Event CT Group HSCT Group ORa* CI95% HSCT Group CT versus (1) CT versus (2)
n/N (%) n/N (%) without
cGVHD (1)
with
cGVHD (2)
ORa* CI95% ORa* CI95%
Height growth failure
Minor or Major 225/687 (32.8) 150/256 (58.6) 4.1 [2.7-6.2] 123/205 (60.0) 27/51 (52.9) 3.7 [2.3-5.7] 4.1 [2.0-8.4]
Major 49/687 (7.1) 82/256 (32.0) 7.9 [4.5-13.9] 66/205 (32.2) 16/51 (31.4) 6.7 [3.7-12.4] 11.8 [4.5-30.9]
GH treatment 3/687 (0.4) 23/256 (9.0) 17.8 [4.0-79.5] 17/205 (8.3) 6/51 (11.8) 11.8 [2.3-60.2] 57.6 [4.8-696.0]
Overweight
Minor or Major 273/687 (39.7) 73/256 (28.5) 0.9 [0.6-1.3] 63/205 (30.7) 10/51 (19.6) 1.0 [0.6-1.5] 0.6 [0.3-1.4]
Major 115/687 (16.7) 29/256 (11.3) 0.8 [0.4-1.4] 26/205 (12.7) 3/51 (5.9) 0.9 [0.5-1.6] 0.5 [0.1-1.8]
Gonadal dysfunction (1) 24/501 (4.8) 105/205 (51.2) 24.4 [12.3-48.1] 85/164 (51.8) 20/41 (48.8) 18.9 [9.4-37.8] 36.5 [11.4-116.3]
Thyroid
Hypothyroidism 10/687 (1.5) 65/256 (25.4) 29.8 [12.7-69.7] 51/205 (24.9) 14/51 (27.5) 26.7 [11.0-64.7] 284.5 [38.9-2083.3]
Malignant thyroid tumor 3/687 (0.4) 8/256 (3.1) 19.7 [3.6-108.0] 7/205 (3.4) 1/51 (2.0) 19.9 [3.4-117.8]
Second tumor
All 20/687 (2.9) 26/256 (10.2) 8.1 [3.3-19.9] 23/205 (11.2) 3/51 (5.9) 7.1 [2.8-18.0] 6.7 [1.3-34.8]
Except BCC and meningioma 14/687 (2.0) 22/256 (8.6) 6.4 [2.5-16.4] 20/205 (9.8) 2/51 (3.9) 6.3 [2.4-16.9] 3.0 [0.4-20.0]
Bone mineral deﬁciency (2) 7 /106 (6.6) 4/57 (7.0) 2.9 [0.4-21.5] 2/42 (4.8) 2/15 (13.3) 1.4 [0.1-12.9] 6.9 [0.5-93.6]
Alopecia 5/687 (0.7) 27/256 (10.5) 13.6 [4.2-44.3] 14/205 (6.8) 13/51 (25.5) 8.9 [2.3-33.9] 60.6 [9.7-380.3]
Cardiac side effect 11/687 (1.6) 13/256 (5.1) 1.0 [0.4-3.0] 9/205 (4.4) 4/51 (7.8) 1.2 [0.4-3.8] 1.4 [0.3-7.0]
Cataract 18/687 (2.6) 97/256 (37.9) 28.9 [14.9-55.7] 78/205 (38.0) 19/51 (37.3) 25.9 [13.0-51.8] 54.8 [18.0-166.9]
Severe neurological dysfunctions 12/687 (1.7) 10/256 (3.9) 2.0 [0.7-6.1] 8/205 (3.9) 2/51 (3.9) 1.8 [0.6-5.9] 2.0 [0.3-12.4]
Diabetes 1/687 (0.1) 5/256 (2.0) 26.0 [1.9-346.8] 4/205 (2.0) 1/51 (2.0) 18.8 [1.1-315.9]
Metabolic syndrome (2) 12/202 (5.9) 14/96 (14.6) 5.5 [1.8-16.8] 9/74 (12.2) 5/22 (22.7) 3.6 [1.0-13.1] 23.4 [4.0-136.8]
Iron overload (3) 30/497 (6.0) 61/196 (31.1) 5.3 [2.6-10.6] 45/159 (28.3) 16/37 (43.2) 5.7 [2.7-12.3] 2.7 [0.8-9.0]
Osteonecrosis 9/687 (1.3) 15/256 (5.9) 5.0 [1.7-14.8] 5/205 (2.4) 10/51 (19.6) 2.0 [0.4-9.1] 21.9 [5.3-90.6]
Viral transmission 9/687 (1.3) 9/256 (3.5) 2.9 [0.7-11.1] 9/205 (4.4) 0/51 (0.0) 3.2 [0.8-12.5]
At least one late event 443/687 (64.5) 231/256 (90.2) 5.0 [3.0-8.6] 183/205 (89.3) 48/51 (94.1) 4.3 [2.5-7.6] 10.0 [2.9-34.6]
CT indicates chemotherapy; HSCT, hematopoietic stem cell transplantation; Ora, adjusted Odds Ratio; CI, conﬁdence interval; GH, growth hormone; BCC, basal
cell carcinoma; CNS, central nervous system; cGVHD, chronic graft-versus-host disease.
n : number of patients w ho experienced the type of long-tem side effect N : number of patients with a valid information.
(1) N ¼ assessable patients (2) N ¼ assessable adults (3) N ¼ serum ferritin dosage performed.
Bold values : ORa signiﬁcant (value 1 w as out of CI95%).
* Reference group : chemotherapy. Co-variables: gender, leukaemia subtype, relapse, age at diagnosis, follow -up duration, CNS irradiation, decade of the start
of treatment.
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consistent with more recently published data on a smaller
sample of patients receiving HSCT [12].
Our studyprovides insighton the effects of childhoodacute
leukemia and its treatmentonQoL. First,when comparedwith
patients treated without HSCT, the transplanted adult pop-
ulation reported a lower level of QoL for the dimensions
describing physical well-being (physical functioning, bodilyTable 3
Effect of Treatment Modalities on QoL in Children and Adolescents (8-17 Years of
Subscales of VSP-Ap Chemotherapy
Group
HSCT
Group
Comparison
n ¼ 251
mean  s.d.
n ¼ 77
mean  s.d.
b P
Psychological well-being 74.8  19.5 77.5  18.6 0.10 .20
Body image 76.5  29.5 66.2  30.2 0.06 .39
Vitality 72.5  16.2 74.3  16.3 0.07 .38
Physical well-being 73.1  19.6 73.0  20.3 0.04 .57
Leisure activities 63.2  21.7 64.9  23.2 0.02 .78
Relationships with friends 66.4  20.3 67.9  18.9 0.02 .82
Relationships with parents 75.3  15.6 75.9  14.4 0.06 .43
Relationships with teachers 68.9  22.2 71.7  18.5 0.16 .04
School work 72.0  22.2 73.7  21.4 0.12 .10
Summary score 71.4  12.5 71.7  12.9 0.07 .36
Relationships with medical staff 56.6  34.6 62.1  32.9 0.18 .02
QoL indicates quality of life; HSCT, haematopoietic stem cell transplantation; s.d
system; cGVHD, chronic graft-versus-host disease.
Bold values: P < 0.05 was signiﬁcant.
* Reference group: chemotherapy. Co-variables: gender, leukaemia subtype, rela
of treatment.pain, general health perceptions), with signiﬁcant effect sizes
up to .48 for the physical composite score. However, no
difference was found in the psychological composite score, as
reported by Ishida et al. [11] on a smaller sample and Arme-
nian et al. [12] using a nonstandardized QoL assessment. As
suggested inourprevious study [10], our current results reﬂect
more precisely the long-term impact of sequelae on QoL
in adults. They are consistent with previous ﬁndings thatAge) Reported by Their Parents: Multivariate Linear Regression Analyses
CT-HSCT* HSCT Group Comparison
without
cGVHD (1)
with
cGVHD (2)
CT-(1)* CT-(2)*
Adjusted-R2 Effect
size
n ¼ 64
mean  s.d.
n ¼ 13
mean  s.d.
P P
0.04 0.14 77.1  18.6 79.4  18.8 .35 .46
0.12 0.35 67.7  29.1 58.8  35.3 .50 .22
0.04 0.11 74.5  15.6 73.1  21.9 .74 .54
0.05 0.01 73.3  20.7 71.6  21.1 .58 .90
0.01 0.08 65.8  23.0 60.1  24.1 .49 .50
0.00 0.07 67.7  19.2 69.2  18.2 .87 .39
0.02 0.04 76.1  14.7 74.8  13.0 .50 .75
0.08 0.13 70.7  19.3 77.1  12.4 .13 .07
0.05 0.08 72.6  22.4 78.8  14.8 .22 .12
0.09 0.02 71.7  12.7 71.5  14.8 .54 .48
0.04 0.16 61.7  33.7 64.4  29.6 .04 .50
., standard deviation; b, standardised b-coefﬁcients; CNS, central nervous
pse, age at diagnosis, follow-up duration, CNS irradiation, decade of the start
Figure 1. Comparison of the QoL assessments by the parents of the LEA survivor cohort of children and adolescents (8-17 years old) and of a French population
sample (VSP-Ap). *French population reference group P < .05 paired for age and sex. LEA indicates parents of the cohort’s children and adolescent (8-17 years old)
survivors; CT, chemotherapy; PsWB, psychological well-being; BI, body image; VIT, vitality; PhWB, physical well-being; LEI, leisure activities; RFr, relationships with
friends; Rpa, relationships with parents; RT, relationships with teachers; SCH, school work.
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observe the negative effects of the treatment on survivors’
health [25,31-33]. The HSCT population reports low levels of
physical QoL , as reported by Ishida et al. [27] or in more
heterogeneous samples, including nontransplantation cancer
patients [34-36]. Interestingly, all survivors of our study,
regardless of the therapeutic management, reported levels of
psychological well-being (mental composite score) signiﬁ-
cantly below the general population norms. Similar results
were not reported by a Finnish study [37] or by studies issued
from the Canadian Childhood Cancer Surveillance and Control
Program [38], the British Childhood Cancer Survivor Study
[31], and the CCSS [39]. However, these results are consistent
with those reported by Hudson et al. [13] comparing adults
who experienced childhood leukemia with the general pop-
ulation. This notable impact on psychological well-being
should be taken into account during the follow-up of survi-
vors in the future.Table 4
Effect of Treatment Modalities on QoL of Adults: Multivariate Linear Regression An
Subscales of SF-36 Chemotherapy
Group
HSCT
Group
Comparison CT-HS
n ¼ 296
mean  s.d.
n ¼ 137
mean  s.d.
b P
Physical functioning 93.0  15.7 88.1  18.6 0.15 .01
Social functioning 80.4  22.1 75.8  23.6 0.05 .41
Role: physical 88.8  24.2 80.6  31.8 0.11 .08
Role: emotional 72.2  26.5 70.1  30.9 0.00 .98
Mental health 67.9  18.8 67.8  17.9 0.06 .30
Vitality 62.3  19.5 61.4  19.6 0.04 .57
Bodily pain 83.7  22.3 76.9  24.1 0.14 .02
General health 75.3  21.1 66.6  22.3 0.21 .001
Physical composite score 55.4  7.1 52.0  8.4 0.25 <.001
Mental composite score 45.1  9.9 45.4  10.0 0.08 .23
QoL indicates quality of life; HSCT, haematopoietic stem cell transplantation; s.d
system; cGVHD, chronic graft-versus-host disease.
Bold values: P < 0.05 was signiﬁcant.
* Reference group: chemotherapy. Co-variables: gender, leukaemia subtype, rela
of treatment.In the adolescent population, transplantation survivors
QoL assessed by their parents was better than in the chemo-
therapy group, although the effect size is small. To our
knowledge, no other results comparing these two populations
on QoL are currently available. Surprisingly, parents of
leukemia survivors, whatever the treatment modality, report
a higher level of QoL for their child than parents of the general
pediatric population, except for the perception of body image
that seems to be altered early by the experience of leukemia.
The impact of HSCT on QoL in childhood leukemia survi-
vors, based on in-depth assessments with well-developed
questionnaires [19], is poorly explored in the literature [40].
Perkins et al. [41] did not show a signiﬁcant difference in the
level of QoLbetween17 childrenwhounderwent grafting and
the standardized norms, whereas Forinder et al. [42] did
report a lower QoL among childrenwho underwent HSCT for
speciﬁc dimensions, such as bodily pain, general health, and
self-esteem, although the general behavior was higher. Ouralyses
CT* HSCT Group Comparison
without
cGVHD (1)
with
cGVHD (2)
CT-(1)* CT-(2)*
Adjusted-R2 Effect
size
n ¼ 108
mean  s.d.
n ¼ 29
mean  s.d.
P P
0.04 0.31 89.5  18.5 82.8  18.5 .14 .004
0.02 0.21 75.9  23.8 75.4  23.3 .58 .59
0.07 0.34 82.3  29.6 74.1  38.7 .25 .09
0.01 0.08 69.8  30.1 71.3  34.2 .68 .66
0.03 0.01 68.0  17.8 67.3  18.8 .18 .67
0.03 0.05 61.7  19.7 60.4  19.4 .63 .57
0.05 0.3 78.6  23.9 70.6  24.2 .14 .01
0.06 0.41 69.1  21.8 57.5  22.0 .04 <.001
0.10 0.48 53.0  7.8 48.2  9.6 .003 <.001
0.01 0.03 45.2  9.6 46.4  11.4 .21 .27
., standard deviation; b, standardised b-coefﬁcients; CNS, central nervous
pse, age at diagnosis, follow-up duration, CNS irradiation, decade of the start
Figure 2. Comparison of the assessment of QoL of the LEA cohort adult survivors and a French population sample (SF-36). *French population reference group P < .05
paired for age and sex. LEA indicates adult survivors; CT, chemotherapy; PF, physical functioning; SF, social functioning; RP, role limitations due to physical health
problems; RE, role limitations due to emotional problems; MH, general mental health; VT, vitality; BP bodily pain; GH, general health perception; PCS, physical
composite score; MCS, mental composite score.
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paring the levels of QoL of children having experienced
leukemia with standardized data [43] as well as with results
reported by Pogorzola et al. [44]. However, Shankar et al. [45]
did not observe a signiﬁcant effect.
Parental reports of QoL in young survivors demonstrates
little difference between treatment groups and higher scores
when compared with French norms. The adult evaluation of
QoL, however, shows signiﬁcant differences between treat-
ment groups and overall decreased scores when compared
with French norms. There are several possible explanations
for the difference between adult survivor perceptions and
those of parents of children. First, the point of viewexpressed
is not the same, because the QoL assessment of adult survi-
vors is self-reported, whereas the QoL assessment of child
survivors is proxy-reported. Second, cognitive adaptation
and coping may also explain this difference in results
depending of the age of survivors. Fertility concerns, such as
hypogonadism, could be experienced differently in adult-
hood than in younger survivors, for instance. Finally, since
1980, changes in treatment of acute leukemia occurred, and
younger survivors are more likely to have received improved
treatment modalities. However, we included the decade of
the start of treatment in our multivariate models, as an
adjusted variable, to take into account the impact of this
evolution in treatment over time.
Occurrence of posttransplantation cGVHD is a potentially
devastating complication,which could inﬂuencebothphysical
sequelae and QoL. This might explain in part the differences
observed between the transplanted and nontransplanted
groups.We explored this hypothesis in secondary analyses by
dividing the transplanted group according to whether or not
posttransplantation cGvHD occurred (Tables 2, 3, and 4).
Transplanted survivors with cGVHD had a higher risk of
having late effects and reported a more altered QoL. Overall,
however, the long-term health status of both subgroups of
transplanted survivors (with orwithout experiencing cGVHD)was adversely affected when compared with survivors
receiving chemotherapy only.
Quality of data collected in this study can be analyzed.
First, a high response rate was observed in the study, and no
signiﬁcant differences were found between respondent and
nonrespondent patients regarding demographic and clinical
characteristics. Furthermore, although the sample size is
smaller than those examined in the most complete national
cohorts performed thus far [25,31], it remains signiﬁcantly
larger than those reported in most studies involving the
same age group [38,43,44,46] or speciﬁcally comparing the
long-term impact of HSCT versus conventional treatment
among childhood leukemia survivors [11,12].
The main aim of this study was to report the results of
a longitudinal French cohort on childhood leukemia survi-
vors. Several cohorts of childhood cancer survivors have been
established. The CCSS remains the most important cohort
[47-49] to report health status based mainly on patient self-
reported outcomes, whereas the LEA study is based on clin-
ical assessments. Although several previous studies have
explored the late effects and QoL in long-term survivors of
childhood cancer, there are several potential limitations to
these studies [50-54]: the population studiedwas not limited
to leukemia survivors and thus was less homogeneous, the
assessment was focused on a speciﬁc age class, QoLmeasures
were compared with a controversial control group such as
siblings or patients suffering from other diseases, and there
were limited samples of transplanted patients [11,12]. In
contrast, the LEA cohort, which includes patients diagnosed
since 1980, allows the study of a large sample of patients who
have undergone HSCT. Nevertheless, given the type of
transplantation and the time frame of therapy, the population
is relatively heterogeneous. We have taken this point into
account in our multivariate models, and further analyses are
in progress to explore the long-term health and QoL of
speciﬁc subgroups within the LEA cohort, especially differ-
ences between allogeneic and autologous transplantation.
J. Berbis et al. / Biol Blood Marrow Transplant 19 (2013) 1065e1072 1071The study found that the population of transplantation
survivors had a higher risk of late effects compared with
survivors treated without HSCT. As a result, adulthood
physical well-being decreased. Whether the patients were
treated with HSCT or not, adults surviving childhood
leukemia reported lower scores on psychological domains of
QoL than the normal population. These ﬁndings should be
better taken into account by healthcare providers.
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